P. Wu, T. E. Nielsen, and M. H. Clausen, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol. Sci, vol.36, pp.422-439, 2015.

L. Zitvogel, S. Rusakiewicz, B. Routy, M. Ayyoub, and G. Kroemer, Immunological off-target effects of imatinib, Nat. Rev. Clin. Oncol, vol.13, pp.431-446, 2016.

M. Bantscheff, Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors, Nat. Biotechnol, vol.25, pp.1035-1044, 2007.

J. Araujo and C. Logothetis, Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors, Cancer Treat. Rev, vol.36, pp.492-500, 2010.

S. Blake, T. P. Hughes, G. Mayrhofer, and A. B. Lyons, The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro, Clin. Immunol. Orlando Fla, vol.127, pp.330-339, 2008.

A. Kreutzman, Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation, Leukemia, vol.25, pp.1587-1597, 2011.

A. E. Schade, Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation, Blood, vol.111, pp.1366-1377, 2008.

J. Salih, The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity, Int. J. Cancer, vol.127, pp.2119-2128, 2010.

C. K. Fraser, Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo, Exp. Hematol, vol.37, pp.256-265, 2009.

C. Hekim, Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models, Cancer Immunol. Res, vol.5, pp.157-169, 2017.

X. Wei, L. He, X. Wang, M. Lin, and J. Dai, Effects of dasatinib on CD8+T, Th1, and Treg cells in patients with chronic myeloid leukemia, J. Int. Med. Res, 2019.

A. Kreutzman, M. Ilander, K. Porkka, J. Vakkila, and S. Mustjoki, Dasatinib promotes Th1-type responses in granzyme B expressing T-cells, Oncoimmunology, vol.3, p.28925, 2014.

K. N. Wu, Dasatinib promotes the potential of proliferation and antitumor responses of human ??T cells in a long-term induction ex vivo environment, Leukemia, vol.28, pp.206-210, 2014.

S. Mustjoki, Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy, Leukemia, vol.27, pp.914-924, 2013.

S. Mustjoki, Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy, Leukemia, vol.23, pp.1398-1405, 2009.

H. Tanaka, S. Nakashima, and M. Usuda, Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients, Int. J. Hematol, vol.96, pp.308-319, 2012.

N. Hassold, Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib, Int. J. Cancer, vol.131, pp.916-927, 2012.

T. Uchiyama, Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study, Hematol. Oncol, vol.31, pp.156-163, 2013.

Y. Najima, Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study, Leuk. Res, vol.66, pp.66-72, 2018.

N. Iriyama, Enhanced perforin expression associated with dasatinib therapy in natural killer cells, Leuk. Res, vol.68, pp.1-8, 2018.

M. Chang, NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia, Front. Immunol, vol.9, p.3152, 2018.

D. I. Godfrey, J. Le-nours, D. M. Andrews, A. P. Uldrich, and J. Rossjohn, Unconventional T Cell Targets for Cancer Immunotherapy, Immunity, vol.48, pp.453-473, 2018.

B. J. Wolf, J. E. Choi, and M. A. Exley, Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy, Front. Immunol, vol.9, p.384, 2018.

A. Rossignol, Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients, Eur. J. Immunol, vol.42, pp.1870-1875, 2012.

S. Basbous, The Rho/ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia, J. Pathol, 2016.

A. Barbarin, Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases, Front. Immunol, vol.8, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01518119

F. Jacomet, Evidence for eomesodermin-expressing innate-like CD8(+) KIR/NKG2A(+) T cells in human adults and cord blood samples, Eur. J. Immunol, vol.45, pp.1926-1933, 2015.

F. Jacomet, The Hypothesis of the Human iNKT/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia, Front. Immunol, vol.7, p.688, 2017.

E. Cayssials, Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells, Br. J. Haematol, 2019.

M. A. Weinreich, O. A. Odumade, S. C. Jameson, and K. A. Hogquist, T cells expressing the transcription factor PLZF regulate the development of memory-like CD8 + T cells, Nat. Immunol, vol.11, pp.709-716, 2010.

D. Lai, KLF13 sustains thymic memory-like CD8 + T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells, J. Exp. Med, vol.208, pp.1093-1103, 2011.

C. Daussy, T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow, J. Exp. Med, vol.211, pp.563-577, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00972070

Y. J. Lee, K. L. Holzapfel, J. Zhu, S. C. Jameson, and K. A. Hogquist, Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells, Nat. Immunol, vol.14, pp.1146-1154, 2013.

J. Park, D. T. Dipalma, J. Kwon, J. Fink, and J. Park, Quantitative Difference in PLZF Protein Expression Determines iNKT Lineage Fate and Controls Innate CD8 T Cell Generation, Cell Rep, vol.27, pp.2548-2557, 2019.

J. J. Powers, A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors, Leuk. Lymphoma, vol.52, pp.668-679, 2011.

P. Rohon, K. Porkka, and S. Mustjoki, Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy, Eur. J. Haematol, vol.85, pp.387-398, 2010.

J. Liu, The peripheral differentiation of human natural killer T cells, Immunol. Cell Biol, vol.97, pp.586-596, 2019.

J. J. Knox, G. L. Cosma, M. R. Betts, and L. M. Mclane, Characterization of T-Bet and Eomes in Peripheral Human Immune Cells, Front. Immunol, vol.5, 2014.

Y. Yang, Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40, Blood, vol.120, pp.4533-4543, 2012.

D. B. Lowe, Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma, Oncoimmunology, vol.3, p.27589, 2014.

H. S. Min, MHC class II-restricted interaction between thymocytes plays an essential role in the production of innate CD8+ T cells, J. Immunol. Baltim. Md, vol.186, pp.5749-5757, 1950.

S. C. Morris, Endogenously produced IL-4 nonredundantly stimulates CD8+ T cell proliferation, J. Immunol. Baltim. Md, vol.182, pp.1429-1438, 1950.

N. Ueda, CD1d-restricted NKT cell activation enhanced homeostatic proliferation of CD8+ T cells in a manner dependent on IL-4, Int. Immunol, vol.18, pp.1397-1404, 2006.

N. S. Baez, Thymic expression of IL-4 and IL-15 after systemic inflammatory or infectious Th1 disease processes induce the acquisition of 'innate' characteristics during CD8+ T cell development, PLoS Pathog, vol.15, p.1007456, 2019.

A. E. Moran, T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse, J. Exp. Med, vol.208, pp.1279-1289, 2011.

S. Söderlund, Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli, Leuk. Res, vol.50, pp.95-103, 2016.

N. P. Goplen, IL-12 Signals through the TCR To Support CD8 Innate Immune Responses, J. Immunol. Baltim. Md, pp.2434-2443, 2016.

M. M. Tu, Targeting DDR2 enhances tumor response to anti-PD-1, immunotherapy. Sci. Adv, vol.5, p.2437, 2019.

G. Yu, Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma, Cell. Mol. Life Sci. CMLS, vol.75, pp.4223-4234, 2018.

K. Mestermann, The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells, Sci. Transl. Med, vol.11, 2019.